




PHARMACEUTICAL 2023

Nurix Therapeutics Inc.
Rank 178 of 446





PHARMACEUTICAL 2023

Nurix Therapeutics Inc.
Rank 178 of 446



The relative strengths and weaknesses of Nurix Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nurix Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Nurix Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 85% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	318,449
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	70,655
Liabilities, Non-Current	42,408
Other Assets	81,147
Other Compr. Net Income	-3,711
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	42,134
Property and Equipment	17,163
Research and Development	184,497
Selling, General and Administrative Expense	37,997

Output Variable	Value in 1000 USD
Assets	416,759
Liabilities	113,063
Expenses	222,494
Revenues	42,134
Stockholders Equity	303,696
Net Income	-180,360
Comprehensive Net Income	-182,216
Economic Capital Ratio	128%